INVITRO STUDIES OF THE EFFECT OF MAB NDA-4 LINKED TO TOXIN ON THE PROLIFERATION OF A HUMAN EBV-TRANSFORMED LYMPHOBLASTOID B-CELL LINE AND OF GIBBON MLA LEUKEMIA-CELL LINE

被引:8
作者
HARRIS, P [1 ]
REED, E [1 ]
KING, DW [1 ]
SUCIUFOCA, N [1 ]
机构
[1] UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637
关键词
D O I
10.1016/0008-8749(91)90333-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The rejection of allografts is mediated by cytolytic T cells and antibody-secreting B cells. Selective ablation of these activated cells from peripheral blood lymphocytes may offer a method of controlling allograft rejection, An immunotoxin was prepared from the monoclonal antibody (mAb) NDA 4, which recognizes a differentation antigen (NDA 4) common to activated B and T cells. MAb NDA 4 was conjugated to the ribosome-inhibiting protein gelonin via a cleavable disulfide bond provided by a crosslinking reagent. The purified immunotoxin was evaluated for in vitro cytotoxicity on NDA 4 positive T and B cell lines, Conjugation of mAb NDA 4 to gelonin increased the in vitro cytotoxicity by a concentration factor of 1000, compared to gelonin alone. The specificity and saturability of mAb NDA 4 binding, as well as the number of antigenic sites per cell on resting versus activated T lymphocytes, were also evaluated. Resting T cells expressed 400-800 sites per cell. PHA-activated T cells and the MLA T cell leukemia expressed 10,000 to 80,000 sites per cell, Peripheral blood mononuclear cells obtained from allografted baboons in quiescence or undergoing rejection were compared for NDA 4 expression by flow cytometry. Lymphocytes obtained from baboons rejecting a heart allograft expressed NDA 4, whereas transplant recipients in quiescence showed no detectable NDA 4, These results suggest that mAb NDA 4-derived immunotoxins may be valuable for the selective depletion of activated lymphocytes while sparing the resting population. © 1991.
引用
收藏
页码:85 / 95
页数:11
相关论文
共 10 条
[1]   NEW PERSPECTIVES ON IMMUNOINTERVENTION IN AUTOIMMUNE-DISEASES [J].
ADORINI, L ;
BARNABA, V ;
BONA, C ;
CELADA, F ;
LANZAVECCHIA, A ;
SERCARZ, E ;
SUCIUFOCA, N ;
WEKERLE, H .
IMMUNOLOGY TODAY, 1990, 11 (11) :383-386
[2]  
CHANTENOUD M, 1988, CURR OPIN IMMUNOL, V1, P235
[3]   AMPLIFICATION OF T-CELL BLASTOGENIC RESPONSES IN HEALTHY-INDIVIDUALS AND PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
HARRIS, PE ;
STRBACECHOVA, K ;
RUBINSTEIN, P ;
MANN, D ;
KING, DW ;
SUCIUFOCA, N .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (03) :746-756
[4]   TOWARDS A BETTER DEFINITION OF HUMAN-LEUKOCYTE SURFACE MOLECULES [J].
KNAPP, W ;
RIEBER, P ;
DORKEN, B ;
SCHMIDT, RE ;
STEIN, H ;
VANDERBORNE, AEGK .
IMMUNOLOGY TODAY, 1989, 10 (08) :253-258
[5]   TRANSPLANTATION - 1988 [J].
MANDEL, TE .
IMMUNOLOGY TODAY, 1989, 10 (01) :1-3
[6]  
MARSH JW, 1988, J BIOL CHEM, V263, P15993
[7]  
STIRPE F, 1980, J BIOL CHEM, V255, P6947
[8]   IMMUNOLOGICAL AND BIOCHEMICAL-CHARACTERIZATION OF AN EPITOPE OF THE TRANSFERRIN RECEPTOR INVOLVED IN THE PRODUCTION OF INTERFERON-GAMMA AND B-CELL GROWTH-FACTOR [J].
SUCIUFOCA, N ;
ROSOCHACKI, SJ ;
CAI, JD ;
REED, E ;
RUBINSTEIN, P ;
KING, DW .
CELLULAR IMMUNOLOGY, 1987, 110 (02) :265-281
[9]  
SUCIUFOCA N, 1988, J IMMUNOL, V140, P395
[10]   A LATE-DIFFERENTIATION ANTIGEN ASSOCIATED WITH THE HELPER INDUCER FUNCTION OF HUMAN T-CELLS [J].
SUCIUFOCA, N ;
REED, E ;
RUBINSTEIN, P ;
MACKENZIE, W ;
NG, AK ;
KING, DW .
NATURE, 1985, 318 (6045) :465-467